Colonics
About Me
Recent Posts
- 'Personality Genes' May Help Account For Longevity
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2381
Last Page | Next Page
1/8/2009
-
Ipsen: FDA's First-Cycle Review Of Reloxin(R) Extended
|
Ipsen (Paris:IPN) announced that the U.S. Food and Drug patronage (FDA) on order notification that the formula Drug User Fee Act (PDUFA) action date for Reloxin® (botulinum toxin of type A) Biologics License form (BLA) in aesthetic indications (glabellar lines) has been broad to April 13, 2009. The FDA did not issue any express request on the occurrence of this extension. More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
